Theriva Biologics Files 8-K on Financials
Ticker: TOVX · Form: 8-K · Filed: Aug 11, 2025 · CIK: 894158
| Field | Detail |
|---|---|
| Company | Theriva Biologics, Inc. (TOVX) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, sec-filing
TL;DR
Theriva Biologics dropped an 8-K on financials, check it for updates.
AI Summary
On August 11, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Theriva Biologics is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting financial condition and results of operations, without immediate news of significant events.
Key Players & Entities
- Theriva Biologics, Inc. (company) — Registrant
- August 11, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-12584 (company_id) — Commission File Number
- 13-3808303 (tax_id) — IRS Employer Identification No.
- 9605 Medical Center Drive (address) — Business address
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the provided excerpt does not detail specific figures.
When was this 8-K report filed?
The report was filed as of August 11, 2025.
What is Theriva Biologics, Inc.'s state of incorporation?
Theriva Biologics, Inc. is incorporated in Nevada.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number for Theriva Biologics, Inc. is 13-3808303.
Has Theriva Biologics, Inc. operated under previous names?
Yes, the company was formerly known as Synthetic Biologics, Inc. (since 2012), ADEONA PHARMACEUTICALS, INC. (since 2008), and PIPEX PHARMACEUTICALS, INC. (since 2006).
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-08-11 08:10:50
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica
Filing Documents
- tm2522967d1_8k.htm (8-K) — 27KB
- tm2522967d1_ex99-1.htm (EX-99.1) — 105KB
- tm2522967d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-25-075944.txt ( ) — 317KB
- syn-20250811.xsd (EX-101.SCH) — 3KB
- syn-20250811_lab.xml (EX-101.LAB) — 33KB
- syn-20250811_pre.xml (EX-101.PRE) — 22KB
- tm2522967d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On August 11, 2025, Theriva Biologics, Inc., a Nevada corporation (the "Registrant") issued a press release that included financial information for its quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated August 11, 2025 104 Cover Page Interactive Data File (embedded within the XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 11, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer